#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=5. Tropism of YFV
1-1	0-2	5.	_	_	_	_
1-2	3-10	Tropism	abstract[1]	new[1]	coref	2-13[8_1]
1-3	11-13	of	abstract[1]	new[1]	_	_
1-4	14-17	YFV	abstract[1]|abstract	new[1]|new	coref	2-8

#Text=In humans , after transcutaneous inoculation , YFV exhibits broad patterns of tissue tropism and is disseminated systemically via infection of multiple white cell subsets .
2-1	18-20	In	_	_	_	_
2-2	21-27	humans	animal	new	coref	4-8
2-3	28-29	,	_	_	_	_
2-4	30-35	after	_	_	_	_
2-5	36-50	transcutaneous	event[4]	new[4]	_	_
2-6	51-62	inoculation	event[4]	new[4]	_	_
2-7	63-64	,	_	_	_	_
2-8	65-68	YFV	abstract	giv	coref	3-34
2-9	69-77	exhibits	_	_	_	_
2-10	78-83	broad	abstract[6]	new[6]	_	_
2-11	84-92	patterns	abstract[6]	new[6]	_	_
2-12	93-95	of	abstract[6]	new[6]	_	_
2-13	96-102	tissue	abstract[6]|object|abstract[8]	new[6]|new|giv[8]	coref|coref	3-4[13_8]|3-25[21_0]
2-14	103-110	tropism	abstract[6]|abstract[8]	new[6]|giv[8]	_	_
2-15	111-114	and	_	_	_	_
2-16	115-117	is	_	_	_	_
2-17	118-130	disseminated	_	_	_	_
2-18	131-143	systemically	_	_	_	_
2-19	144-147	via	_	_	_	_
2-20	148-157	infection	event[9]	new[9]	coref	5-36[42_9]
2-21	158-160	of	event[9]	new[9]	_	_
2-22	161-169	multiple	event[9]|animal[11]	new[9]|new[11]	_	_
2-23	170-175	white	event[9]|place[10]|animal[11]	new[9]|new[10]|new[11]	_	_
2-24	176-180	cell	event[9]|place[10]|animal[11]	new[9]|new[10]|new[11]	_	_
2-25	181-188	subsets	event[9]|animal[11]	new[9]|new[11]	_	_
2-26	189-190	.	_	_	_	_

#Text=With respect to organ tropism , the liver is the primary target , although the heart , kidneys , liver , spleen , and less frequently , the brain tissue , can support YFV replication .
3-1	191-195	With	_	_	_	_
3-2	196-203	respect	_	_	_	_
3-3	204-206	to	_	_	_	_
3-4	207-212	organ	abstract|abstract[13]	new|giv[13]	_	_
3-5	213-220	tropism	abstract[13]	giv[13]	_	_
3-6	221-222	,	_	_	_	_
3-7	223-226	the	abstract[14]	new[14]	coref	3-10[15_14]
3-8	227-232	liver	abstract[14]	new[14]	_	_
3-9	233-235	is	_	_	_	_
3-10	236-239	the	abstract[15]	giv[15]	coref	3-20[0_15]
3-11	240-247	primary	abstract[15]	giv[15]	_	_
3-12	248-254	target	abstract[15]	giv[15]	_	_
3-13	255-256	,	_	_	_	_
3-14	257-265	although	_	_	_	_
3-15	266-269	the	object[16]	new[16]	_	_
3-16	270-275	heart	object[16]	new[16]	_	_
3-17	276-277	,	_	_	_	_
3-18	278-285	kidneys	object	new	_	_
3-19	286-287	,	_	_	_	_
3-20	288-293	liver	abstract	giv	_	_
3-21	294-295	,	_	_	_	_
3-22	296-302	spleen	object	new	_	_
3-23	303-304	,	_	_	_	_
3-24	305-308	and	_	_	_	_
3-25	309-313	less	object[21]	giv[21]	coref	13-19[105_21]
3-26	314-324	frequently	object[21]	giv[21]	_	_
3-27	325-326	,	object[21]	giv[21]	_	_
3-28	327-330	the	object[21]	giv[21]	_	_
3-29	331-336	brain	object|object[21]	new|giv[21]	coref	13-11[101_0]
3-30	337-343	tissue	object[21]	giv[21]	_	_
3-31	344-345	,	_	_	_	_
3-32	346-349	can	_	_	_	_
3-33	350-357	support	_	_	_	_
3-34	358-361	YFV	abstract|event[23]	giv|new[23]	coref|coref	4-6|10-13[0_23]
3-35	362-373	replication	event[23]	new[23]	_	_
3-36	374-375	.	_	_	_	_

#Text=The natural host range of YFV includes humans , non-human primates and mosquitos .
4-1	376-379	The	abstract[25]	new[25]	_	_
4-2	380-387	natural	abstract[25]	new[25]	_	_
4-3	388-392	host	person|abstract[25]	new|new[25]	coref	8-6
4-4	393-398	range	abstract[25]	new[25]	_	_
4-5	399-401	of	abstract[25]	new[25]	_	_
4-6	402-405	YFV	abstract[25]|abstract	new[25]|giv	coref	5-34
4-7	406-414	includes	_	_	_	_
4-8	415-421	humans	animal|animal[28]	giv|giv[28]	coref|coref	4-8[28_0]|8-29[0_28]
4-9	422-423	,	animal[28]	giv[28]	_	_
4-10	424-433	non-human	animal[28]|animal[29]	giv[28]|new[29]	coref	7-16[54_29]
4-11	434-442	primates	animal[28]|animal[29]	giv[28]|new[29]	_	_
4-12	443-446	and	animal[28]	giv[28]	_	_
4-13	447-456	mosquitos	animal[28]|animal	giv[28]|new	coref	16-7
4-14	457-458	.	_	_	_	_

#Text=Additionally , wild animals from the diverse orders Artiodactyla , Carnivora and the superorder Xenarthra have been reported to be serologically positive for anti-YFV antibodies , and the elicitation of antibody responses against YFV indicates a potentially productive infection within these species , indicating that diverse mammalian species could represent YFV potential reservoirs ( see Section 8.3 ) .
5-1	459-471	Additionally	_	_	_	_
5-2	472-473	,	_	_	_	_
5-3	474-478	wild	animal[31]	new[31]	coref	11-16[86_31]
5-4	479-486	animals	animal[31]	new[31]	_	_
5-5	487-491	from	animal[31]	new[31]	_	_
5-6	492-495	the	animal[31]|animal[32]|abstract[33]	new[31]|new[32]|new[33]	_	_
5-7	496-503	diverse	animal[31]|animal[32]|abstract[33]	new[31]|new[32]|new[33]	_	_
5-8	504-510	orders	animal[31]|animal[32]|abstract[33]	new[31]|new[32]|new[33]	_	_
5-9	511-523	Artiodactyla	animal[31]|abstract[33]	new[31]|new[33]	_	_
5-10	524-525	,	animal[31]	new[31]	_	_
5-11	526-535	Carnivora	animal[31]|animal	new[31]|new	_	_
5-12	536-539	and	animal[31]	new[31]	_	_
5-13	540-543	the	animal[31]|abstract[36]	new[31]|new[36]	_	_
5-14	544-554	superorder	animal[31]|abstract|abstract[36]	new[31]|new|new[36]	_	_
5-15	555-564	Xenarthra	animal[31]|abstract[36]	new[31]|new[36]	_	_
5-16	565-569	have	_	_	_	_
5-17	570-574	been	_	_	_	_
5-18	575-583	reported	_	_	_	_
5-19	584-586	to	_	_	_	_
5-20	587-589	be	_	_	_	_
5-21	590-603	serologically	_	_	_	_
5-22	604-612	positive	_	_	_	_
5-23	613-616	for	_	_	_	_
5-24	617-625	anti-YFV	substance[37]	new[37]	_	_
5-25	626-636	antibodies	substance[37]	new[37]	_	_
5-26	637-638	,	_	_	_	_
5-27	639-642	and	_	_	_	_
5-28	643-646	the	abstract[38]	new[38]	_	_
5-29	647-658	elicitation	abstract[38]	new[38]	_	_
5-30	659-661	of	abstract[38]	new[38]	_	_
5-31	662-670	antibody	abstract[38]|substance|abstract[40]	new[38]|new|new[40]	_	_
5-32	671-680	responses	abstract[38]|abstract[40]	new[38]|new[40]	_	_
5-33	681-688	against	abstract[38]|abstract[40]	new[38]|new[40]	_	_
5-34	689-692	YFV	abstract[38]|abstract[40]|abstract	new[38]|new[40]|giv	coref	5-51
5-35	693-702	indicates	_	_	_	_
5-36	703-704	a	event[42]	giv[42]	_	_
5-37	705-716	potentially	event[42]	giv[42]	_	_
5-38	717-727	productive	event[42]	giv[42]	_	_
5-39	728-737	infection	event[42]	giv[42]	_	_
5-40	738-744	within	event[42]	giv[42]	_	_
5-41	745-750	these	event[42]|animal[43]	giv[42]|new[43]	coref	5-46[44_43]
5-42	751-758	species	event[42]|animal[43]	giv[42]|new[43]	_	_
5-43	759-760	,	_	_	_	_
5-44	761-771	indicating	_	_	_	_
5-45	772-776	that	_	_	_	_
5-46	777-784	diverse	animal[44]	giv[44]	_	_
5-47	785-794	mammalian	animal[44]	giv[44]	_	_
5-48	795-802	species	animal[44]	giv[44]	_	_
5-49	803-808	could	_	_	_	_
5-50	809-818	represent	_	_	_	_
5-51	819-822	YFV	abstract|abstract[46]	giv|new[46]	coref|coref	6-4|10-11[78_46]
5-52	823-832	potential	abstract[46]	new[46]	_	_
5-53	833-843	reservoirs	abstract[46]	new[46]	_	_
5-54	844-845	(	_	_	_	_
5-55	846-849	see	_	_	_	_
5-56	850-857	Section	abstract[47]	new[47]	_	_
5-57	858-861	8.3	abstract[47]	new[47]	_	_
5-58	862-863	)	_	_	_	_
5-59	864-865	.	_	_	_	_

#Text=Mouse Models for YFV
6-1	866-871	Mouse	abstract[48]	new[48]	coref	10-7[75_48]
6-2	872-878	Models	abstract[48]	new[48]	_	_
6-3	879-882	for	abstract[48]	new[48]	_	_
6-4	883-886	YFV	abstract[48]|abstract	new[48]|giv	coref	7-1

#Text=YFV research is currently limited as it remains challenging and expensive to establish workflows with non-human primates .
7-1	887-890	YFV	abstract|abstract[51]	giv|new[51]	ana|coref	7-7[0_51]|8-2
7-2	891-899	research	abstract[51]	new[51]	_	_
7-3	900-902	is	_	_	_	_
7-4	903-912	currently	_	_	_	_
7-5	913-920	limited	_	_	_	_
7-6	921-923	as	_	_	_	_
7-7	924-926	it	abstract	giv	_	_
7-8	927-934	remains	_	_	_	_
7-9	935-946	challenging	_	_	_	_
7-10	947-950	and	_	_	_	_
7-11	951-960	expensive	_	_	_	_
7-12	961-963	to	_	_	_	_
7-13	964-973	establish	_	_	_	_
7-14	974-983	workflows	abstract	new	_	_
7-15	984-988	with	_	_	_	_
7-16	989-998	non-human	animal[54]	giv[54]	coref	12-14[0_54]
7-17	999-1007	primates	animal[54]	giv[54]	_	_
7-18	1008-1009	.	_	_	_	_

#Text=While YFV has a limited host species-tropism , artificial infection of laboratory mice and hamsters is possible , although the course of disease differs from that observed in humans .
8-1	1010-1015	While	_	_	_	_
8-2	1016-1019	YFV	abstract	giv	coref	9-17
8-3	1020-1023	has	_	_	_	_
8-4	1024-1025	a	animal[57]	new[57]	_	_
8-5	1026-1033	limited	animal[57]	new[57]	_	_
8-6	1034-1038	host	person|animal[57]	giv|new[57]	coref	23-13
8-7	1039-1054	species-tropism	animal[57]	new[57]	_	_
8-8	1055-1056	,	_	_	_	_
8-9	1057-1067	artificial	event[58]	new[58]	coref	9-17[68_58]
8-10	1068-1077	infection	event[58]	new[58]	_	_
8-11	1078-1080	of	event[58]	new[58]	_	_
8-12	1081-1091	laboratory	event[58]|animal[59]	new[58]|new[59]	coref	9-8[65_59]
8-13	1092-1096	mice	event[58]|animal[59]	new[58]|new[59]	_	_
8-14	1097-1100	and	event[58]	new[58]	_	_
8-15	1101-1109	hamsters	event[58]|animal	new[58]|new	_	_
8-16	1110-1112	is	_	_	_	_
8-17	1113-1121	possible	_	_	_	_
8-18	1122-1123	,	_	_	_	_
8-19	1124-1132	although	_	_	_	_
8-20	1133-1136	the	abstract[61]	new[61]	coref	20-30[179_61]
8-21	1137-1143	course	abstract[61]	new[61]	_	_
8-22	1144-1146	of	abstract[61]	new[61]	_	_
8-23	1147-1154	disease	abstract[61]|abstract	new[61]|new	coref	20-21[175_0]
8-24	1155-1162	differs	_	_	_	_
8-25	1163-1167	from	_	_	_	_
8-26	1168-1172	that	_	_	_	_
8-27	1173-1181	observed	_	_	_	_
8-28	1182-1184	in	_	_	_	_
8-29	1185-1191	humans	animal	giv	coref	12-16
8-30	1192-1193	.	_	_	_	_

#Text=Nevertheless , a number of studies in genetically modified or humanized mice have yielded insights into YFV infection and dissemination in vivo .
9-1	1194-1206	Nevertheless	_	_	_	_
9-2	1207-1208	,	_	_	_	_
9-3	1209-1210	a	event[64]	new[64]	coref	23-3[206_64]
9-4	1211-1217	number	event[64]	new[64]	_	_
9-5	1218-1220	of	event[64]	new[64]	_	_
9-6	1221-1228	studies	event[64]	new[64]	_	_
9-7	1229-1231	in	event[64]	new[64]	_	_
9-8	1232-1243	genetically	event[64]|animal[65]	new[64]|giv[65]	coref	11-1[83_65]
9-9	1244-1252	modified	event[64]|animal[65]	new[64]|giv[65]	_	_
9-10	1253-1255	or	event[64]|animal[65]	new[64]|giv[65]	_	_
9-11	1256-1265	humanized	event[64]|animal[65]	new[64]|giv[65]	_	_
9-12	1266-1270	mice	event[64]|animal[65]	new[64]|giv[65]	_	_
9-13	1271-1275	have	_	_	_	_
9-14	1276-1283	yielded	_	_	_	_
9-15	1284-1292	insights	abstract[66]	new[66]	_	_
9-16	1293-1297	into	abstract[66]	new[66]	_	_
9-17	1298-1301	YFV	abstract[66]|abstract|event[68]	new[66]|giv|giv[68]	coref|coref	10-12|11-23[89_68]
9-18	1302-1311	infection	abstract[66]|event[68]	new[66]|giv[68]	_	_
9-19	1312-1315	and	abstract[66]	new[66]	_	_
9-20	1316-1329	dissemination	abstract[66]|abstract	new[66]|new	coref	10-4[73_0]
9-21	1330-1332	in	_	_	_	_
9-22	1333-1337	vivo	abstract	new	coref	11-27
9-23	1338-1339	.	_	_	_	_

#Text=Single cell-tracking of YFV-17D dissemination in different mouse models identified novel YFV replication reservoirs in secondary lymphoid compartments , with hematopoietic STAT1 knockout increasing virus-induced pathogenicity .
10-1	1340-1346	Single	abstract[71]	new[71]	_	_
10-2	1347-1360	cell-tracking	abstract[71]	new[71]	_	_
10-3	1361-1363	of	abstract[71]	new[71]	_	_
10-4	1364-1371	YFV-17D	abstract[71]|abstract|abstract[73]	new[71]|new|giv[73]	coref|coref	13-17|16-4[0_73]
10-5	1372-1385	dissemination	abstract[71]|abstract[73]	new[71]|giv[73]	_	_
10-6	1386-1388	in	abstract[71]	new[71]	_	_
10-7	1389-1398	different	abstract[71]|abstract[75]	new[71]|giv[75]	coref	19-32[165_75]
10-8	1399-1404	mouse	abstract[71]|animal|abstract[75]	new[71]|new|giv[75]	coref	19-32
10-9	1405-1411	models	abstract[71]|abstract[75]	new[71]|giv[75]	_	_
10-10	1412-1422	identified	_	_	_	_
10-11	1423-1428	novel	abstract[78]	giv[78]	_	_
10-12	1429-1432	YFV	abstract|abstract[78]	giv|giv[78]	coref	11-24
10-13	1433-1444	replication	event|abstract[78]	giv|giv[78]	coref	21-17[185_0]
10-14	1445-1455	reservoirs	abstract[78]	giv[78]	_	_
10-15	1456-1458	in	abstract[78]	giv[78]	_	_
10-16	1459-1468	secondary	abstract[78]|place[79]	giv[78]|new[79]	coref	11-29[91_79]
10-17	1469-1477	lymphoid	abstract[78]|place[79]	giv[78]|new[79]	_	_
10-18	1478-1490	compartments	abstract[78]|place[79]	giv[78]|new[79]	_	_
10-19	1491-1492	,	_	_	_	_
10-20	1493-1497	with	_	_	_	_
10-21	1498-1511	hematopoietic	abstract[81]	new[81]	_	_
10-22	1512-1517	STAT1	abstract|abstract[81]	new|new[81]	coref	20-7
10-23	1518-1526	knockout	abstract[81]	new[81]	_	_
10-24	1527-1537	increasing	_	_	_	_
10-25	1538-1551	virus-induced	abstract[82]	new[82]	_	_
10-26	1552-1565	pathogenicity	abstract[82]	new[82]	_	_
10-27	1566-1567	.	_	_	_	_

#Text=Double-humanized mice have been developed , possessing both human immune systems and hepatocytes , and these animals represent ideal tools for monitoring systemic YFV infection in vivo as both compartments are permissive for YFV .
11-1	1568-1584	Double-humanized	animal[83]	giv[83]	coref	14-22[114_83]
11-2	1585-1589	mice	animal[83]	giv[83]	_	_
11-3	1590-1594	have	_	_	_	_
11-4	1595-1599	been	_	_	_	_
11-5	1600-1609	developed	_	_	_	_
11-6	1610-1611	,	_	_	_	_
11-7	1612-1622	possessing	_	_	_	_
11-8	1623-1627	both	abstract[84]	new[84]	_	_
11-9	1628-1633	human	abstract[84]	new[84]	_	_
11-10	1634-1640	immune	abstract[84]	new[84]	_	_
11-11	1641-1648	systems	abstract[84]	new[84]	_	_
11-12	1649-1652	and	_	_	_	_
11-13	1653-1664	hepatocytes	substance	new	_	_
11-14	1665-1666	,	_	_	_	_
11-15	1667-1670	and	_	_	_	_
11-16	1671-1676	these	animal[86]	giv[86]	_	_
11-17	1677-1684	animals	animal[86]	giv[86]	_	_
11-18	1685-1694	represent	_	_	_	_
11-19	1695-1700	ideal	object[87]	new[87]	_	_
11-20	1701-1706	tools	object[87]	new[87]	_	_
11-21	1707-1710	for	object[87]	new[87]	_	_
11-22	1711-1721	monitoring	object[87]	new[87]	_	_
11-23	1722-1730	systemic	object[87]|event[89]	new[87]|giv[89]	_	_
11-24	1731-1734	YFV	object[87]|abstract|event[89]	new[87]|giv|giv[89]	coref	11-34
11-25	1735-1744	infection	object[87]|event[89]	new[87]|giv[89]	_	_
11-26	1745-1747	in	object[87]	new[87]	_	_
11-27	1748-1752	vivo	object[87]|abstract	new[87]|giv	coref	23-16
11-28	1753-1755	as	_	_	_	_
11-29	1756-1760	both	place[91]	giv[91]	_	_
11-30	1761-1773	compartments	place[91]	giv[91]	_	_
11-31	1774-1777	are	_	_	_	_
11-32	1778-1788	permissive	_	_	_	_
11-33	1789-1792	for	_	_	_	_
11-34	1793-1796	YFV	abstract	giv	coref	12-6
11-35	1797-1798	.	_	_	_	_

#Text=In addition to hepatotropism , YFV can also be neurotropic in rodents , primates and humans .
12-1	1799-1801	In	_	_	_	_
12-2	1802-1810	addition	_	_	_	_
12-3	1811-1813	to	_	_	_	_
12-4	1814-1827	hepatotropism	animal	new	_	_
12-5	1828-1829	,	_	_	_	_
12-6	1830-1833	YFV	abstract	giv	coref	21-21
12-7	1834-1837	can	_	_	_	_
12-8	1838-1842	also	_	_	_	_
12-9	1843-1845	be	_	_	_	_
12-10	1846-1857	neurotropic	_	_	_	_
12-11	1858-1860	in	_	_	_	_
12-12	1861-1868	rodents	animal	new	_	_
12-13	1869-1870	,	_	_	_	_
12-14	1871-1879	primates	animal	giv	_	_
12-15	1880-1883	and	_	_	_	_
12-16	1884-1890	humans	animal	giv	coref	20-27
12-17	1891-1892	.	_	_	_	_

#Text=In contrast to polio virus and reovirus , which infect the brain via the CNS , YFV-17D infects brain tissue by crossing the blood-brain barrier .
13-1	1893-1895	In	_	_	_	_
13-2	1896-1904	contrast	_	_	_	_
13-3	1905-1907	to	_	_	_	_
13-4	1908-1913	polio	person|abstract[99]	new|new[99]	coref	16-13[129_99]
13-5	1914-1919	virus	abstract[99]	new[99]	_	_
13-6	1920-1923	and	_	_	_	_
13-7	1924-1932	reovirus	abstract[100]	new[100]	_	_
13-8	1933-1934	,	abstract[100]	new[100]	_	_
13-9	1935-1940	which	abstract[100]	new[100]	_	_
13-10	1941-1947	infect	abstract[100]	new[100]	_	_
13-11	1948-1951	the	abstract[100]|object[101]	new[100]|giv[101]	coref	13-19[0_101]
13-12	1952-1957	brain	abstract[100]|object[101]	new[100]|giv[101]	_	_
13-13	1958-1961	via	abstract[100]	new[100]	_	_
13-14	1962-1965	the	abstract[100]|abstract[102]	new[100]|new[102]	_	_
13-15	1966-1969	CNS	abstract[100]|abstract[102]	new[100]|new[102]	_	_
13-16	1970-1971	,	_	_	_	_
13-17	1972-1979	YFV-17D	abstract	giv	coref	18-6
13-18	1980-1987	infects	_	_	_	_
13-19	1988-1993	brain	object|object[105]	giv|giv[105]	coref	17-11[0_105]
13-20	1994-2000	tissue	object[105]	giv[105]	_	_
13-21	2001-2003	by	_	_	_	_
13-22	2004-2012	crossing	_	_	_	_
13-23	2013-2016	the	abstract[106]	new[106]	_	_
13-24	2017-2028	blood-brain	abstract[106]	new[106]	_	_
13-25	2029-2036	barrier	abstract[106]	new[106]	_	_
13-26	2037-2038	.	_	_	_	_

#Text=A mouse-neurovirulent strain ( SPYF ) based on the Porterfield 17D ( PYF17D ) strain was derived by additional passaging in SCID mice , exhibiting enhanced neurovirulence and neuroinvasiveness .
14-1	2039-2040	A	abstract[107]	new[107]	appos	14-5[0_107]
14-2	2041-2060	mouse-neurovirulent	abstract[107]	new[107]	_	_
14-3	2061-2067	strain	abstract[107]	new[107]	_	_
14-4	2068-2069	(	_	_	_	_
14-5	2070-2074	SPYF	abstract	giv	coref	14-9[111_0]
14-6	2075-2076	)	_	_	_	_
14-7	2077-2082	based	_	_	_	_
14-8	2083-2085	on	_	_	_	_
14-9	2086-2089	the	abstract[111]	giv[111]	_	_
14-10	2090-2101	Porterfield	person|abstract[111]	new|giv[111]	_	_
14-11	2102-2105	17D	abstract[111]	giv[111]	_	_
14-12	2106-2107	(	abstract[111]	giv[111]	_	_
14-13	2108-2114	PYF17D	abstract|abstract[111]	new|giv[111]	_	_
14-14	2115-2116	)	abstract[111]	giv[111]	_	_
14-15	2117-2123	strain	abstract[111]	giv[111]	_	_
14-16	2124-2127	was	_	_	_	_
14-17	2128-2135	derived	_	_	_	_
14-18	2136-2138	by	_	_	_	_
14-19	2139-2149	additional	event[112]	new[112]	_	_
14-20	2150-2159	passaging	event[112]	new[112]	_	_
14-21	2160-2162	in	_	_	_	_
14-22	2163-2167	SCID	animal|animal[114]	new|giv[114]	coref	18-9[142_114]
14-23	2168-2172	mice	animal[114]	giv[114]	_	_
14-24	2173-2174	,	_	_	_	_
14-25	2175-2185	exhibiting	_	_	_	_
14-26	2186-2194	enhanced	abstract[115]	new[115]	_	_
14-27	2195-2209	neurovirulence	abstract[115]	new[115]	_	_
14-28	2210-2213	and	_	_	_	_
14-29	2214-2231	neuroinvasiveness	abstract	new	_	_
14-30	2232-2233	.	_	_	_	_

#Text=This enhanced neurotopism was correlated with 13 amino acid substitutions , five of which were located in the E protein .
15-1	2234-2238	This	abstract[117]	new[117]	_	_
15-2	2239-2247	enhanced	abstract[117]	new[117]	_	_
15-3	2248-2259	neurotopism	abstract[117]	new[117]	_	_
15-4	2260-2263	was	_	_	_	_
15-5	2264-2274	correlated	_	_	_	_
15-6	2275-2279	with	_	_	_	_
15-7	2280-2282	13	abstract[120]	new[120]	_	_
15-8	2283-2288	amino	object|substance[119]|abstract[120]	new|new[119]|new[120]	_	_
15-9	2289-2293	acid	substance[119]|abstract[120]	new[119]|new[120]	_	_
15-10	2294-2307	substitutions	abstract[120]	new[120]	_	_
15-11	2308-2309	,	abstract[120]	new[120]	_	_
15-12	2310-2314	five	abstract[120]|time[121]	new[120]|new[121]	_	_
15-13	2315-2317	of	abstract[120]|time[121]	new[120]|new[121]	_	_
15-14	2318-2323	which	abstract[120]|time[121]	new[120]|new[121]	_	_
15-15	2324-2328	were	abstract[120]	new[120]	_	_
15-16	2329-2336	located	abstract[120]	new[120]	_	_
15-17	2337-2339	in	abstract[120]	new[120]	_	_
15-18	2340-2343	the	abstract[120]|substance[123]	new[120]|new[123]	_	_
15-19	2344-2345	E	abstract[120]|person|substance[123]	new[120]|new|new[123]	_	_
15-20	2346-2353	protein	abstract[120]|substance[123]	new[120]|new[123]	_	_
15-21	2354-2355	.	_	_	_	_

#Text=Arboviruses can encounter dissemination barriers in mosquitos , restricting the spreading of the virus within the vector species .
16-1	2356-2367	Arboviruses	animal	new	_	_
16-2	2368-2371	can	_	_	_	_
16-3	2372-2381	encounter	_	_	_	_
16-4	2382-2395	dissemination	abstract|abstract[126]	giv|new[126]	ana|coref	17-1[0_126]|18-6[141_0]
16-5	2396-2404	barriers	abstract[126]	new[126]	_	_
16-6	2405-2407	in	_	_	_	_
16-7	2408-2417	mosquitos	animal	giv	_	_
16-8	2418-2419	,	_	_	_	_
16-9	2420-2431	restricting	_	_	_	_
16-10	2432-2435	the	event[128]	new[128]	_	_
16-11	2436-2445	spreading	event[128]	new[128]	_	_
16-12	2446-2448	of	event[128]	new[128]	_	_
16-13	2449-2452	the	event[128]|abstract[129]	new[128]|giv[129]	_	_
16-14	2453-2458	virus	event[128]|abstract[129]	new[128]|giv[129]	_	_
16-15	2459-2465	within	event[128]	new[128]	_	_
16-16	2466-2469	the	event[128]|animal[131]	new[128]|new[131]	_	_
16-17	2470-2476	vector	event[128]|animal|animal[131]	new[128]|new|new[131]	_	_
16-18	2477-2484	species	event[128]|animal[131]	new[128]|new[131]	_	_
16-19	2485-2486	.	_	_	_	_

#Text=These include innate immunity related pathways as well as physical tissue barriers associated with the midgut and salivary glands .
17-1	2487-2492	These	abstract	giv	coref	17-10[136_0]
17-2	2493-2500	include	_	_	_	_
17-3	2501-2507	innate	abstract[134]	new[134]	_	_
17-4	2508-2516	immunity	abstract|abstract[134]	new|new[134]	_	_
17-5	2517-2524	related	abstract[134]	new[134]	_	_
17-6	2525-2533	pathways	abstract[134]	new[134]	_	_
17-7	2534-2536	as	_	_	_	_
17-8	2537-2541	well	_	_	_	_
17-9	2542-2544	as	_	_	_	_
17-10	2545-2553	physical	abstract[136]	giv[136]	coref	18-29[148_136]
17-11	2554-2560	tissue	object|abstract[136]	giv|giv[136]	_	_
17-12	2561-2569	barriers	abstract[136]	giv[136]	_	_
17-13	2570-2580	associated	abstract[136]	giv[136]	_	_
17-14	2581-2585	with	abstract[136]	giv[136]	_	_
17-15	2586-2589	the	abstract[136]|animal[137]	giv[136]|new[137]	_	_
17-16	2590-2596	midgut	abstract[136]|animal[137]	giv[136]|new[137]	_	_
17-17	2597-2600	and	abstract[136]	giv[136]	_	_
17-18	2601-2609	salivary	abstract[136]|object[138]	giv[136]|new[138]	_	_
17-19	2610-2616	glands	abstract[136]|object[138]	giv[136]|new[138]	_	_
17-20	2617-2618	.	_	_	_	_

#Text=However , while patterns of YFV-17D dissemination in immunocompetent mice were restricted , infection of IFNAR knockout mice resulted in broad dissemination preceding viral clearance , indicating that no barriers to dissemination exist in the absence of type I IFN .
18-1	2619-2626	However	_	_	_	_
18-2	2627-2628	,	_	_	_	_
18-3	2629-2634	while	_	_	_	_
18-4	2635-2643	patterns	abstract[139]	new[139]	_	_
18-5	2644-2646	of	abstract[139]	new[139]	_	_
18-6	2647-2654	YFV-17D	abstract[139]|abstract|abstract[141]	new[139]|giv|giv[141]	coref|coref	18-21[146_141]|19-13
18-7	2655-2668	dissemination	abstract[139]|abstract[141]	new[139]|giv[141]	_	_
18-8	2669-2671	in	abstract[139]	new[139]	_	_
18-9	2672-2687	immunocompetent	abstract[139]|animal[142]	new[139]|giv[142]	coref	18-16[145_142]
18-10	2688-2692	mice	abstract[139]|animal[142]	new[139]|giv[142]	_	_
18-11	2693-2697	were	_	_	_	_
18-12	2698-2708	restricted	_	_	_	_
18-13	2709-2710	,	_	_	_	_
18-14	2711-2720	infection	event[143]	new[143]	coref	19-13[158_143]
18-15	2721-2723	of	event[143]	new[143]	_	_
18-16	2724-2729	IFNAR	event[143]|abstract|animal[145]	new[143]|new|giv[145]	coref	20-4[172_145]
18-17	2730-2738	knockout	event[143]|animal[145]	new[143]|giv[145]	_	_
18-18	2739-2743	mice	event[143]|animal[145]	new[143]|giv[145]	_	_
18-19	2744-2752	resulted	_	_	_	_
18-20	2753-2755	in	_	_	_	_
18-21	2756-2761	broad	abstract[146]	giv[146]	coref	18-32[0_146]
18-22	2762-2775	dissemination	abstract[146]	giv[146]	_	_
18-23	2776-2785	preceding	abstract[146]	giv[146]	_	_
18-24	2786-2791	viral	abstract[146]|abstract[147]	giv[146]|new[147]	_	_
18-25	2792-2801	clearance	abstract[146]|abstract[147]	giv[146]|new[147]	_	_
18-26	2802-2803	,	_	_	_	_
18-27	2804-2814	indicating	_	_	_	_
18-28	2815-2819	that	_	_	_	_
18-29	2820-2822	no	abstract[148]	giv[148]	_	_
18-30	2823-2831	barriers	abstract[148]	giv[148]	_	_
18-31	2832-2834	to	abstract[148]	giv[148]	_	_
18-32	2835-2848	dissemination	abstract[148]|abstract	giv[148]|giv	coref	23-10[210_0]
18-33	2849-2854	exist	_	_	_	_
18-34	2855-2857	in	_	_	_	_
18-35	2858-2861	the	abstract[150]	new[150]	_	_
18-36	2862-2869	absence	abstract[150]	new[150]	_	_
18-37	2870-2872	of	abstract[150]	new[150]	_	_
18-38	2873-2877	type	abstract[150]|abstract|abstract[153]	new[150]|new|new[153]	coref|coref	19-7|19-16[160_153]
18-39	2878-2879	I	abstract[150]|person|abstract[153]	new[150]|new|new[153]	_	_
18-40	2880-2883	IFN	abstract[150]|abstract[153]	new[150]|new[153]	_	_
18-41	2884-2885	.	_	_	_	_

#Text=Furthermore , while I and II type IFNs contribute to control of YFV-17D infection , type III IFN was demonstrated to have immunomodulatory functions and was protective against YFV-17D neuroinvasion in mouse models .
19-1	2886-2897	Furthermore	_	_	_	_
19-2	2898-2899	,	_	_	_	_
19-3	2900-2905	while	_	_	_	_
19-4	2906-2907	I	abstract[155]	new[155]	_	_
19-5	2908-2911	and	abstract[155]	new[155]	_	_
19-6	2912-2914	II	abstract[155]	new[155]	_	_
19-7	2915-2919	type	abstract|abstract[155]	giv|new[155]	coref	19-16[159_0]
19-8	2920-2924	IFNs	abstract[155]	new[155]	_	_
19-9	2925-2935	contribute	_	_	_	_
19-10	2936-2938	to	_	_	_	_
19-11	2939-2946	control	abstract[156]	new[156]	coref	23-13[212_156]
19-12	2947-2949	of	abstract[156]	new[156]	_	_
19-13	2950-2957	YFV-17D	abstract[156]|abstract|event[158]	new[156]|giv|giv[158]	coref|coref	19-29|20-14[173_158]
19-14	2958-2967	infection	abstract[156]|event[158]	new[156]|giv[158]	_	_
19-15	2968-2969	,	_	_	_	_
19-16	2970-2974	type	abstract[159]|abstract[160]	giv[159]|giv[160]	coref	21-12[0_160]
19-17	2975-2978	III	abstract[159]|abstract[160]	giv[159]|giv[160]	_	_
19-18	2979-2982	IFN	abstract[160]	giv[160]	_	_
19-19	2983-2986	was	_	_	_	_
19-20	2987-2999	demonstrated	_	_	_	_
19-21	3000-3002	to	_	_	_	_
19-22	3003-3007	have	_	_	_	_
19-23	3008-3024	immunomodulatory	abstract[161]	new[161]	_	_
19-24	3025-3034	functions	abstract[161]	new[161]	_	_
19-25	3035-3038	and	_	_	_	_
19-26	3039-3042	was	_	_	_	_
19-27	3043-3053	protective	_	_	_	_
19-28	3054-3061	against	_	_	_	_
19-29	3062-3069	YFV-17D	abstract|abstract[163]	giv|new[163]	_	_
19-30	3070-3083	neuroinvasion	abstract[163]	new[163]	_	_
19-31	3084-3086	in	_	_	_	_
19-32	3087-3092	mouse	animal|abstract[165]	giv|giv[165]	coref|coref	23-4|24-13[219_165]
19-33	3093-3099	models	abstract[165]	giv[165]	_	_
19-34	3100-3101	.	_	_	_	_

#Text=YFD-17D infection of IFN-α/β receptor and STAT1 signaling molecule deficient mice resulted in systemic viscerotropic infection : a course of disease which resembles that observed in humans rather than the typical encephalitic disease course commonly reported for mice .
20-1	3102-3109	YFD-17D	object|event[167]	new|new[167]	_	_
20-2	3110-3119	infection	event[167]	new[167]	_	_
20-3	3120-3122	of	event[167]	new[167]	_	_
20-4	3123-3130	IFN-α/β	event[167]|abstract|abstract[171]|animal[172]	new[167]|new|new[171]|giv[172]	coref	20-38[0_172]
20-5	3131-3139	receptor	event[167]|substance|abstract[171]|animal[172]	new[167]|new|new[171]|giv[172]	_	_
20-6	3140-3143	and	event[167]|abstract[171]|animal[172]	new[167]|new[171]|giv[172]	_	_
20-7	3144-3149	STAT1	event[167]|abstract|abstract[171]|animal[172]	new[167]|giv|new[171]|giv[172]	_	_
20-8	3150-3159	signaling	event[167]|abstract[171]|animal[172]	new[167]|new[171]|giv[172]	_	_
20-9	3160-3168	molecule	event[167]|abstract[171]|animal[172]	new[167]|new[171]|giv[172]	_	_
20-10	3169-3178	deficient	event[167]|animal[172]	new[167]|giv[172]	_	_
20-11	3179-3183	mice	event[167]|animal[172]	new[167]|giv[172]	_	_
20-12	3184-3192	resulted	_	_	_	_
20-13	3193-3195	in	_	_	_	_
20-14	3196-3204	systemic	event[173]	giv[173]	_	_
20-15	3205-3218	viscerotropic	event[173]	giv[173]	_	_
20-16	3219-3228	infection	event[173]	giv[173]	_	_
20-17	3229-3230	:	_	_	_	_
20-18	3231-3232	a	abstract[174]	new[174]	_	_
20-19	3233-3239	course	abstract[174]	new[174]	_	_
20-20	3240-3242	of	abstract[174]	new[174]	_	_
20-21	3243-3250	disease	abstract[174]|abstract[175]	new[174]|giv[175]	ana	20-24[176_175]
20-22	3251-3256	which	abstract[174]|abstract[175]	new[174]|giv[175]	_	_
20-23	3257-3266	resembles	abstract[174]|abstract[175]	new[174]|giv[175]	_	_
20-24	3267-3271	that	abstract[174]|abstract[175]|abstract[176]	new[174]|giv[175]|giv[176]	coref	20-33[0_176]
20-25	3272-3280	observed	abstract[174]|abstract[175]|abstract[176]	new[174]|giv[175]|giv[176]	_	_
20-26	3281-3283	in	abstract[174]|abstract[175]|abstract[176]	new[174]|giv[175]|giv[176]	_	_
20-27	3284-3290	humans	abstract[174]|abstract[175]|abstract[176]|animal	new[174]|giv[175]|giv[176]|giv	coref	24-30
20-28	3291-3297	rather	_	_	_	_
20-29	3298-3302	than	_	_	_	_
20-30	3303-3306	the	abstract[179]	giv[179]	coref	24-25[222_179]
20-31	3307-3314	typical	abstract[179]	giv[179]	_	_
20-32	3315-3327	encephalitic	abstract[179]	giv[179]	_	_
20-33	3328-3335	disease	abstract|abstract[179]	giv|giv[179]	coref	24-15
20-34	3336-3342	course	abstract[179]	giv[179]	_	_
20-35	3343-3351	commonly	abstract[179]	giv[179]	_	_
20-36	3352-3360	reported	abstract[179]	giv[179]	_	_
20-37	3361-3364	for	abstract[179]	giv[179]	_	_
20-38	3365-3369	mice	abstract[179]|animal	giv[179]|giv	_	_
20-39	3370-3371	.	_	_	_	_

#Text=Finally , while many flaviviruses share the common ability to antagonize IFN signaling and therefore enhance viral replication , the YFV NS5 is unable to bind murine STAT2 and in contrast to ZIKV and DENV , is unable to engage human STAT2 in murine cells .
21-1	3372-3379	Finally	_	_	_	_
21-2	3380-3381	,	_	_	_	_
21-3	3382-3387	while	_	_	_	_
21-4	3388-3392	many	animal[181]	new[181]	_	_
21-5	3393-3405	flaviviruses	animal[181]	new[181]	_	_
21-6	3406-3411	share	_	_	_	_
21-7	3412-3415	the	abstract[182]	new[182]	_	_
21-8	3416-3422	common	abstract[182]	new[182]	_	_
21-9	3423-3430	ability	abstract[182]	new[182]	_	_
21-10	3431-3433	to	abstract[182]	new[182]	_	_
21-11	3434-3444	antagonize	abstract[182]	new[182]	_	_
21-12	3445-3448	IFN	abstract[182]|abstract|abstract[184]	new[182]|giv|new[184]	_	_
21-13	3449-3458	signaling	abstract[182]|abstract[184]	new[182]|new[184]	_	_
21-14	3459-3462	and	abstract[182]	new[182]	_	_
21-15	3463-3472	therefore	abstract[182]	new[182]	_	_
21-16	3473-3480	enhance	abstract[182]	new[182]	_	_
21-17	3481-3486	viral	abstract[182]|event[185]	new[182]|giv[185]	coref	22-7[198_185]
21-18	3487-3498	replication	abstract[182]|event[185]	new[182]|giv[185]	_	_
21-19	3499-3500	,	_	_	_	_
21-20	3501-3504	the	abstract[187]	new[187]	coref	22-21[0_187]
21-21	3505-3508	YFV	abstract|abstract[187]	giv|new[187]	coref	22-7
21-22	3509-3512	NS5	abstract[187]	new[187]	_	_
21-23	3513-3515	is	_	_	_	_
21-24	3516-3522	unable	_	_	_	_
21-25	3523-3525	to	_	_	_	_
21-26	3526-3530	bind	_	_	_	_
21-27	3531-3537	murine	animal|abstract[189]	new|new[189]	coref|coref	21-41[192_189]|21-44
21-28	3538-3543	STAT2	abstract[189]	new[189]	_	_
21-29	3544-3547	and	_	_	_	_
21-30	3548-3550	in	_	_	_	_
21-31	3551-3559	contrast	_	_	_	_
21-32	3560-3562	to	_	_	_	_
21-33	3563-3567	ZIKV	abstract	new	_	_
21-34	3568-3571	and	_	_	_	_
21-35	3572-3576	DENV	abstract	new	_	_
21-36	3577-3578	,	_	_	_	_
21-37	3579-3581	is	_	_	_	_
21-38	3582-3588	unable	_	_	_	_
21-39	3589-3591	to	_	_	_	_
21-40	3592-3598	engage	_	_	_	_
21-41	3599-3604	human	abstract[192]	giv[192]	coref	22-1[196_192]
21-42	3605-3610	STAT2	abstract[192]	giv[192]	_	_
21-43	3611-3613	in	_	_	_	_
21-44	3614-3620	murine	animal|object[194]	giv|new[194]	coref|coref	22-1|22-10[200_194]
21-45	3621-3626	cells	object[194]	new[194]	_	_
21-46	3627-3628	.	_	_	_	_

#Text=Murine STAT2 was demonstrated to repress YFV replication in murine cells , which was correlated with an absence of IFN-α/β-mediated NS5 ubiquitination .
22-1	3629-3635	Murine	animal|abstract[196]	giv|giv[196]	coref	22-10
22-2	3636-3641	STAT2	abstract[196]	giv[196]	_	_
22-3	3642-3645	was	_	_	_	_
22-4	3646-3658	demonstrated	_	_	_	_
22-5	3659-3661	to	_	_	_	_
22-6	3662-3669	repress	_	_	_	_
22-7	3670-3673	YFV	abstract|event[198]	giv|giv[198]	coref	23-10
22-8	3674-3685	replication	event[198]	giv[198]	_	_
22-9	3686-3688	in	_	_	_	_
22-10	3689-3695	murine	animal|object[200]	giv|giv[200]	_	_
22-11	3696-3701	cells	object[200]	giv[200]	_	_
22-12	3702-3703	,	_	_	_	_
22-13	3704-3709	which	_	_	_	_
22-14	3710-3713	was	_	_	_	_
22-15	3714-3724	correlated	_	_	_	_
22-16	3725-3729	with	_	_	_	_
22-17	3730-3732	an	abstract[201]	new[201]	_	_
22-18	3733-3740	absence	abstract[201]	new[201]	_	_
22-19	3741-3743	of	abstract[201]	new[201]	_	_
22-20	3744-3760	IFN-α/β-mediated	abstract[201]|abstract|abstract[204]	new[201]|new|new[204]	_	_
22-21	3761-3764	NS5	abstract[201]|abstract|abstract[204]	new[201]|giv|new[204]	_	_
22-22	3765-3779	ubiquitination	abstract[201]|abstract[204]	new[201]|new[204]	_	_
22-23	3780-3781	.	_	_	_	_

#Text=Together , these mouse studies enhance our understanding of YFV dissemination and host control in vivo .
23-1	3782-3790	Together	_	_	_	_
23-2	3791-3792	,	_	_	_	_
23-3	3793-3798	these	event[206]	giv[206]	_	_
23-4	3799-3804	mouse	animal|event[206]	giv|giv[206]	coref	25-8
23-5	3805-3812	studies	event[206]	giv[206]	_	_
23-6	3813-3820	enhance	_	_	_	_
23-7	3821-3824	our	person|abstract[208]	acc|new[208]	_	_
23-8	3825-3838	understanding	abstract[208]	new[208]	_	_
23-9	3839-3841	of	abstract[208]	new[208]	_	_
23-10	3842-3845	YFV	abstract[208]|abstract|abstract[210]	new[208]|giv|giv[210]	coref	24-18
23-11	3846-3859	dissemination	abstract[208]|abstract[210]	new[208]|giv[210]	_	_
23-12	3860-3863	and	abstract[208]	new[208]	_	_
23-13	3864-3868	host	abstract[208]|person|abstract[212]	new[208]|giv|giv[212]	_	_
23-14	3869-3876	control	abstract[208]|abstract[212]	new[208]|giv[212]	_	_
23-15	3877-3879	in	abstract[208]|abstract[212]	new[208]|giv[212]	_	_
23-16	3880-3884	vivo	abstract[208]|abstract[212]|abstract	new[208]|giv[212]|giv	_	_
23-17	3885-3886	.	_	_	_	_

#Text=These findings are useful for the development of the next generation of small animal disease models for YFV , which should endeavor to recapitulate the disease course seen in humans .
24-1	3887-3892	These	abstract[214]	new[214]	_	_
24-2	3893-3901	findings	abstract[214]	new[214]	_	_
24-3	3902-3905	are	_	_	_	_
24-4	3906-3912	useful	_	_	_	_
24-5	3913-3916	for	_	_	_	_
24-6	3917-3920	the	event[215]	new[215]	_	_
24-7	3921-3932	development	event[215]	new[215]	_	_
24-8	3933-3935	of	event[215]	new[215]	_	_
24-9	3936-3939	the	event[215]|abstract[216]	new[215]|new[216]	_	_
24-10	3940-3944	next	event[215]|abstract[216]	new[215]|new[216]	_	_
24-11	3945-3955	generation	event[215]|abstract[216]	new[215]|new[216]	_	_
24-12	3956-3958	of	event[215]|abstract[216]	new[215]|new[216]	_	_
24-13	3959-3964	small	event[215]|abstract[216]|person[217]|abstract[219]	new[215]|new[216]|new[217]|giv[219]	_	_
24-14	3965-3971	animal	event[215]|abstract[216]|person[217]|abstract[219]	new[215]|new[216]|new[217]|giv[219]	_	_
24-15	3972-3979	disease	event[215]|abstract[216]|abstract|abstract[219]	new[215]|new[216]|giv|giv[219]	coref	24-26
24-16	3980-3986	models	event[215]|abstract[216]|abstract[219]	new[215]|new[216]|giv[219]	_	_
24-17	3987-3990	for	event[215]|abstract[216]|abstract[219]	new[215]|new[216]|giv[219]	_	_
24-18	3991-3994	YFV	event[215]|abstract[216]|abstract[219]|abstract	new[215]|new[216]|giv[219]|giv	coref	25-32
24-19	3995-3996	,	event[215]|abstract[216]|abstract[219]	new[215]|new[216]|giv[219]	_	_
24-20	3997-4002	which	event[215]|abstract[216]|abstract[219]	new[215]|new[216]|giv[219]	_	_
24-21	4003-4009	should	event[215]|abstract[216]|abstract[219]	new[215]|new[216]|giv[219]	_	_
24-22	4010-4018	endeavor	event[215]|abstract[216]|abstract[219]	new[215]|new[216]|giv[219]	_	_
24-23	4019-4021	to	event[215]|abstract[216]|abstract[219]	new[215]|new[216]|giv[219]	_	_
24-24	4022-4034	recapitulate	event[215]|abstract[216]|abstract[219]	new[215]|new[216]|giv[219]	_	_
24-25	4035-4038	the	event[215]|abstract[216]|abstract[219]|abstract[222]	new[215]|new[216]|giv[219]|giv[222]	_	_
24-26	4039-4046	disease	event[215]|abstract[216]|abstract[219]|abstract|abstract[222]	new[215]|new[216]|giv[219]|giv|giv[222]	_	_
24-27	4047-4053	course	event[215]|abstract[216]|abstract[219]|abstract[222]	new[215]|new[216]|giv[219]|giv[222]	_	_
24-28	4054-4058	seen	event[215]|abstract[216]|abstract[219]|abstract[222]	new[215]|new[216]|giv[219]|giv[222]	_	_
24-29	4059-4061	in	event[215]|abstract[216]|abstract[219]|abstract[222]	new[215]|new[216]|giv[219]|giv[222]	_	_
24-30	4062-4068	humans	event[215]|abstract[216]|abstract[219]|abstract[222]|animal	new[215]|new[216]|giv[219]|giv[222]|giv	_	_
24-31	4069-4070	.	_	_	_	_

#Text=Thus , the generation of an immunocompetent mouse model would be beneficial , which could be realized by knocking out downstream specific anti-YFV effectors that directly inhibit differential aspects of the YFV lifecycle , rather than upstream master-regulators of the antiviral response .
25-1	4071-4075	Thus	_	_	_	_
25-2	4076-4077	,	_	_	_	_
25-3	4078-4081	the	event[224]	new[224]	_	_
25-4	4082-4092	generation	event[224]	new[224]	_	_
25-5	4093-4095	of	event[224]	new[224]	_	_
25-6	4096-4098	an	event[224]|abstract[226]	new[224]|new[226]	_	_
25-7	4099-4114	immunocompetent	event[224]|abstract[226]	new[224]|new[226]	_	_
25-8	4115-4120	mouse	event[224]|animal|abstract[226]	new[224]|giv|new[226]	_	_
25-9	4121-4126	model	event[224]|abstract[226]	new[224]|new[226]	_	_
25-10	4127-4132	would	_	_	_	_
25-11	4133-4135	be	_	_	_	_
25-12	4136-4146	beneficial	_	_	_	_
25-13	4147-4148	,	_	_	_	_
25-14	4149-4154	which	_	_	_	_
25-15	4155-4160	could	_	_	_	_
25-16	4161-4163	be	_	_	_	_
25-17	4164-4172	realized	_	_	_	_
25-18	4173-4175	by	_	_	_	_
25-19	4176-4184	knocking	_	_	_	_
25-20	4185-4188	out	_	_	_	_
25-21	4189-4199	downstream	abstract[227]	new[227]	_	_
25-22	4200-4208	specific	abstract[227]	new[227]	_	_
25-23	4209-4217	anti-YFV	abstract[227]	new[227]	_	_
25-24	4218-4227	effectors	abstract[227]	new[227]	_	_
25-25	4228-4232	that	abstract[227]	new[227]	_	_
25-26	4233-4241	directly	abstract[227]	new[227]	_	_
25-27	4242-4249	inhibit	abstract[227]	new[227]	_	_
25-28	4250-4262	differential	abstract[227]|abstract[228]	new[227]|new[228]	_	_
25-29	4263-4270	aspects	abstract[227]|abstract[228]	new[227]|new[228]	_	_
25-30	4271-4273	of	abstract[227]|abstract[228]	new[227]|new[228]	_	_
25-31	4274-4277	the	abstract[227]|abstract[228]|abstract[230]	new[227]|new[228]|new[230]	_	_
25-32	4278-4281	YFV	abstract[227]|abstract[228]|abstract|abstract[230]	new[227]|new[228]|giv|new[230]	_	_
25-33	4282-4291	lifecycle	abstract[227]|abstract[228]|abstract[230]	new[227]|new[228]|new[230]	_	_
25-34	4292-4293	,	_	_	_	_
25-35	4294-4300	rather	_	_	_	_
25-36	4301-4305	than	_	_	_	_
25-37	4306-4314	upstream	person[231]	new[231]	_	_
25-38	4315-4332	master-regulators	person[231]	new[231]	_	_
25-39	4333-4335	of	person[231]	new[231]	_	_
25-40	4336-4339	the	person[231]|abstract[232]	new[231]|new[232]	_	_
25-41	4340-4349	antiviral	person[231]|abstract[232]	new[231]|new[232]	_	_
25-42	4350-4358	response	person[231]|abstract[232]	new[231]|new[232]	_	_
25-43	4359-4360	.	_	_	_	_

#Text=Screening approaches could identify such factors .
26-1	4361-4370	Screening	abstract[233]	new[233]	_	_
26-2	4371-4381	approaches	abstract[233]	new[233]	_	_
26-3	4382-4387	could	_	_	_	_
26-4	4388-4396	identify	_	_	_	_
26-5	4397-4401	such	abstract[234]	new[234]	_	_
26-6	4402-4409	factors	abstract[234]	new[234]	_	_
26-7	4410-4411	.	_	_	_	_
